Voyager Therapeutics' anti-tau monoclonal antibody VY7523 demonstrated an excellent safety and PK profile in phase 1 SAD.
Very likely not, at least not as long as MAHA embraces quackery and antivax pseudoscience—not that that didn't stop STAT News from ignoring the elephant in the room, vaccines, in sear ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results